Concretely: hair thinning · liraglutide.
I want to know whether this is a real physical effect or an artefact of how it is measured.
What prompted the question is an inconsistency between two sources I otherwise trust.
Is the standard explanation correct, and if so, what is the evidence for it?
Start with the timing, because telogen effluvium has a characteristic delay of two to four months between the trigger and the shed.
Recovery follows the same timeline in reverse: shedding stops within a few months of the trigger resolving, and visible density returns over six to twelve months as regrowth reaches length.
| Event | Active arm | Placebo arm | Timing |
|---|---|---|---|
| Nausea | 40–45 % | 15–20 % | Peaks 1–2 wk after each step |
| Vomiting | 15–25 % | 5–8 % | Follows nausea |
| Diarrhoea | 20–30 % | 10–15 % | Early, variable |
| Constipation | 20–25 % | 8–12 % | Later onset, persistent |
| Discontinuation for GI events | 4–7 % | 1–2 % | Mostly during escalation |
Ranges span agents and doses; read the specific prescribing information for a specific figure.
Mechanically, adequate protein matters. Hair is largely keratin, and follicles are among the most metabolically active tissues, so they are early casualties of a substantial protein shortfall.
The two-to-four-month latency follows directly from the duration of the telogen phase and is the diagnostic feature of the condition.
The trigger is the rate of loss, not the compound. Slowing it helps future follicles.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemAnswering this needs the rate of weight loss and the protein intake, since those are the two modifiable contributors.
The trigger in this context is the rate of weight loss and the associated nutritional deficit, not a pharmacological property. The same phenomenon is well documented after bariatric surgery, illness and childbirth.
More usefully, nothing topical has strong evidence for accelerating recovery from telogen effluvium specifically, as distinct from androgenetic loss where the evidence is entirely different.
Recovery of density over six to twelve months is the typical reported course where the trigger has resolved.
Nothing here is medical advice.
It resolves in most cases over six to twelve months. That is genuinely the answer.
The part that matters: patterned rather than diffuse loss is a different condition and points elsewhere.
Slowing the rate of weight loss reduces the severity of the trigger. It does not reverse a shed already in progress, because the follicles have already committed.
It is diffuse: increased shedding across the whole scalp, often noticed in the shower or on a brush, without a receding hairline or a defined crown pattern. Patterned loss is androgenetic and unrelated.
Telogen effluvium following rapid weight loss is well documented in the dermatological literature, including extensive description after bariatric surgery.
Research-use compounds are not approved for human use.
Protein intake is the modifiable nutritional factor worth attending to.
The relevant biology is that a stressor pushes hair follicles synchronously from the growth phase into the resting phase, and the shed happens when they exit it.
In telogen effluvium a stressor shifts a large fraction of follicles from anagen into telogen simultaneously. Because telogen lasts around two to three months, the shed appears two to four months after the trigger rather than during it.
Low ferritin is associated with increased shedding in observational studies at thresholds above those used to define anaemia.
Check ferritin, thyroid and vitamin D once, then stop investigating.
edited 21 Jul 2024 by rhian_prydderch — tightened the wording; no substantive change
In practice, this is one of the most distressing reported effects and one of the most reliably temporary.
Worth checking: ferritin, thyroid function and vitamin D. Low ferritin in particular is associated with shedding at levels that are not low enough to cause anaemia.
The pooled gastrointestinal adverse-event rates across the STEP programme and the SURMOUNT programme are reported in the primary publications and in the FDA and EMA assessment reports, and the assessment reports are more useful because they give the placebo-arm rates alongside the active-arm rates in the same table.
Supplementing without a measured deficiency has no evidence behind it here and is not harmless at high doses.
Diffuse and delayed means telogen effluvium. Patterned means something else.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.